Companies 0 See All
Hedge Funds 0 See All
Insiders 0 See All
Institutional Investors 0 See All
Click here to see all results for
Home > Insider Trading > Filing (0001179110-17-010224)

Filing Details

Accession Number:
0001179110-17-010224
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-07-07 16:55:22
Reporting Period:
2017-07-05
Filing Date:
2017-07-07
Accepted Time:
2017-07-07 16:55:22
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1280600 Acceleron Pharma Inc XLRN Biological Products, (No Disgnostic Substances) (2836) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1325710 L Matthew Sherman 128 Sidney Street
Cambridge MA 02139		 Evp & Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Show Other Fields >>
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-07-05 8,000 $7.12 112,400 No 4 M Direct
Common Stock Disposition 2017-07-05 16,000 $32.00 96,400 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Show Other Fields >>
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Option to Purchase Common Stock Disposition 2017-07-05 8,000 $0.00 8,000 $7.12
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2022-12-12 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 8,500 Indirect By Irrevocable Trust
Footnotes
  1. The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  2. The options of registrant's common stock vest in equal quarterly installments over the first four years after the grant.